Jiangsu Hengrui Pharma A/H Listing - PHIP Updates and Updated Thoughts on A/H Premium

423 Views08 May 2025 09:48

Jiangsu Hengrui Medicine (600276 CH) (JHP), a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing. In this note, we talk about the recent updates.

What is covered in the Full Insight:

Introduction to Jiangsu Hengrui Pharma
Recent Financial Performance
Focus on Innovative Drugs
Stock Performance and Analyst Views
Valuations and A/H Premium Analysis

Sumeet Singh

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 5-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream